ACHIEVE LIFE SCIENCES, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ACHV in the last 30 days.
See all $ACHV insider activity →Achieve Life Sciences granted its CFO, Benjamin Halladay, 200,000 stock options and 200,000 restricted stock units (RSUs). The options have a $7.01 exercise price and expire in 2036, vesting over four years. The RSUs vest annually from 2027 to 2030. Both awards are contingent on Halladay's continued service.
Achieve Life Sciences (ACHV) granted stock options and RSUs to new hires, including 200,000 shares each to its new CFO. The awards vest over four years. Achieve is developing cytisinicline for nicotine dependence, with an NDA supported by Phase 3 studies and Breakthrough Therapy designation for vaping cessation.
ACHIEVE LIFE SCIENCES, INC. (ACHV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 1, 2026, Achieve Life Sciences, Inc. (the “ Company ”) announced that the Board of Directors of the Company (th
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ACHV (ACHIEVE LIFE SCIENCES, INC.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent ACHV coverage spans financial news, corporate actions and insider activity.
The grant increases Halladay's alignment with shareholders and may signal confidence in the company's future, but the dilution effect is modest.
Equity dilution from new grants may exert slight downward pressure on the stock.
New CFO appointment with a $525k salary and equity awards may affect investor perception of management quality.
New CFO appointment may influence future financial strategy and investor sentiment.
Analyst upgrade and price target may drive buying interest.
AlphAI scores every news story that mentions ACHV with an AI model for sentiment and relevance, and aggregates insider trades from ACHIEVE LIFE SCIENCES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Achieve Life Sciences granted its CFO, Benjamin Halladay, 200,000 stock options and 200,000 restricted stock units (RSUs). The options have a $7.01 exercise price and expire in 2036, vesting over four years. The RSUs vest annually from 2027 to 2030. Both awards are contingent on Halladay's continued service.
1 min readAchieve Life Sciences (ACHV) granted stock options and RSUs to new hires, including 200,000 shares each to its new CFO. The awards vest over four years. Achieve is developing cytisinicline for nicotine dependence, with an NDA supported by Phase 3 studies and Breakthrough Therapy designation for vaping cessation.
1 min readACHIEVE LIFE SCIENCES, INC. (ACHV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 1, 2026, Achieve Life Sciences, Inc. (the “ Company ”) announced that the Board of Directors of the Company (th
1 min readAchieve Life Sciences (ACHV) named Benjamin Halladay as CFO, starting October 5, 2026. He previously served as CFO at Esperion Therapeutics from 2022 to 2026.
1 min readStifel initiated Achieve Life Sciences (ACHV) with a Buy rating, citing the potential of its smoking cessation drug cytisinicline. The firm set a $ price target, implying 134% upside from the September 29 close, according to analyst James Condulis.
1 min readAchieve Life (ACHV) director Richard Alistair Stewart sold 20,626 shares at an average price of $8.493, retaining 208,249 shares directly and 1,241 indirectly. The sale occurred on August 19, 2026, with prices ranging from $8.4536 to $8.52 per share.
1 min readStewart Richard Alistair sold 20,626 shares of ACHIEVE LIFE SCIENCES, INC. (ACHV) at $8.49 ($0.18M total) on 2026-08-19.
1 min readAchieve Life Sciences (ACHV) reported that Logos Global Management LP and related funds filed a Schedule 13G showing passive beneficial ownership of 10,538,440 shares, or 9.99% of the class, based on 102,902,490 shares outstanding as of Aug. 11, 2026. Holdings include 6,951,032 shares, options for 1,000,000 shares, and warrants for 2,751,032 shares.
2 min readACHIEVE LIFE SCIENCES, INC. (ACHV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following
6 min readAchieve Life Sciences (Nasdaq: ACHV) reported Q2 2026 results and updates on cytisinicline for nicotine dependence. The FDA issued a Complete Response Letter on June 20, 2026 citing cGMP and labeling issues, with no clinical efficacy or safety deficiencies. Achieve closed a private placement up to $354M and expects NDA resubmission in Q4 2026 and potential FDA approval in H1 2027. Cash was $187.3M at June 30, 2026.
6 min read